Importantly, antibody-drug conjugate (ADC) therapies designed to target HER2 or HER3 significantly diminish prostate cancer cell growth in vitro and tumor size in vivo, despite ASPN in the TME. The gene discussed is ERBB2; the disease is Familial prostate cancer.